Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MicroRNAs changed in response to HDGF treatment

ABSTRACT: MicroRNAs changed in response to HDGF treatment

PROVIDER: PRJNA637108 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

MicroRNAs changed in response to HDGF treatment

Project description:We determined the RNAs which were suggested to commonly increase or decrease in HepG2 and SK-Hep1 cells in response to exogenously supplied hepatoma-derived growth factor (HDGF).

2022-06-01 | GSE151762 | GEO

Circulating MicroRNAs and Treatment Response in Childhood Asthma

Project description:Circulating MicroRNAs and Treatment Response in Childhood Asthma

| PRJNA556710 | ENA

Next Generation Sequencing Facilitates Quantitative Analysis of Changed MicroRNAs in Psoriasis Patients.

Project description:Purpose: MicroRNAs are small noncoding RNAs involved in autoimmune diseases. The goals of this study are to identify changed miRNAs in the peripheral blood mononuclear cell (PBMC) of psoriasis patients. Results: Gene ontology analysis showed that obviously changed genes enriched in autoimmune disease related pathways, suggesting miR-148a is important in autoimmune responses. 990 protein-coding genes upregulated in their mRNA abundance in miR-148a-/- monocytes on day 0, and 1036 genes in miR-148a-/- monocytes on day 3. Among them, 136 genes were found upregulation on both day 0 and 3 in miR-148a-/- monocytes.

2019-12-23 | GSE142510 | GEO

Proteomics of U1810 cells upon treatment with microRNAs with an AAGUGC seed motif.

Project description:microRNA dysregulation is a common feature of cancer cells, but the complex roles of microRNAs in cancer are not fully elucidated. Here we used functional genomics to identify oncogenic microRNAs in non-small cell lung cancer and to evaluate their impact on response to EGFR targeting therapy. Our data demonstrate that microRNAs with an AAGUGC-motif in their seed-sequence increase both cancer cell proliferation and sensitivity to EGFR inhibitors. Global transcriptomics, proteomics and target prediction resulted in the identification of several tumor suppressors involved in the G1/S transition as targets of AAGUGC-microRNAs. The clinical implications of our findings were evaluated by analysis of public domain data supporting the link between this microRNA seed-family, their tumor suppressor targets and cancer cell proliferation. In conclusion we propose that AAGUGC-microRNAs are an integral part of an oncogenic signaling network, and that these findings have potential therapeutic implications, especially in selecting patients for EGFR-targeting therapy.

2017-03-31 | MSV000080829 | MassIVE

Proteomics of U1810 cells upon treatment with microRNAs with an AAGUGC seed motif.

2016-06-28 | PXD004163 | Pride

Next Generation Sequencing Facilitates Quantitative Analysis of Changed MicroRNAs in Psoriasis Patients.

Project description:Next Generation Sequencing Facilitates Quantitative Analysis of Changed MicroRNAs in Psoriasis Patients.

| PRJNA597231 | ENA

Serum exosome microRNAs predict multiple sclerosis disease activity after fingolimod treatment

Project description:Background: We and others have previously demonstrated the potential for circulating exosome microRNAs to aid in disease diagnosis. In this study, we sought the possible utility of serum exosome microRNAs as biomarkers for disease activity in multiple sclerosis patients in response to fingolimod therapy. We studied patients with relapsing-remitting multiple sclerosis prior to and 6 months after treatment with fingolimod. Methods: Disease activity was determined using gadolinium-enhanced magnetic resonance imaging. Serum exosome microRNAs were profiled using next-generation sequencing. Data were analysed using univariate/multivariate modelling and machine learning to determine microRNA signatures with predictive utility. Results: we identified 15 individual miRNAs that were differentially expressed in serum exosomes from post-treatment patients with active versus quiescent disease. The targets of these microRNAs clustered in ontologies related to the immune and nervous systems, and signal transduction. While the power of individual microRNAs to predict disease status post-fingolimod was modest (average 77%, range 65 to 91%), several combinations of 2 or 3 miRNAs were able to distinguish active from quiescent disease with greater than 90% accuracy. Further stratification of patients identified additional microRNAs associated with stable remission, and a positive response to fingolimod in patients with active disease prior to treatment. Conclusions: Overall, these data underscore the value of serum exosome microRNA signatures as non-invasive biomarkers of disease in multiple sclerosis and suggest they may be used to predict response to fingolimod in future clinical practice. Additionally, these data suggest that fingolimod may have mechanisms of action beyond its known functions.

2019-11-08 | GSE140106 | GEO

Serum microRNAs as biomarkers for the therapeutic response to trastuzumab/pertuzumab/taxane therapy in HER2-positive metastatic breast cancer

Project description:Serum microRNAs profiles of HER2 positive advanced breast cancer patients and their treatment response after the trastuzumab/pertuzumab/taxane therapy

2022-11-04 | GSE122426 | GEO

MicroRNAs and mRNAs differentially expressed in 5 glioblastoma spheroid cultures upon ATRA treatment

Project description:Microarray-based gene expression analysis identified microRNAs and mRNAs differentially expressed in 5 glioblastoma spheroid cultures upon ATRA treatment.

2010-07-20 | GSE17227 | GEO

Grapevine response to Beauveria bassiana treatment

Project description:Grapevine response to Beauveria bassiana treatment

| PRJNA547582 | ENA